RWM
IOVA icon

Rialto Wealth Management’s Iovance Biotherapeutics IOVA Stock Holding History

Rialto Wealth Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-131
Closed -$437 – 1732
2025
Q1 		$437 Buy
+131
New +$676 ﹤0.01% 952

Other funds holding IOVA

MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Rialto Wealth Management's IOVA Position: Q2 2025 in Review

Rialto Wealth Management sold out of Iovance Biotherapeutics (IOVA) in Q2 2025, closing a stake of 131 shares — an estimated $437 sold.

Rialto Wealth Management first reported a position in IOVA in Q1 2025 and held it in 1 quarter. The position peaked at $437 in Q1 2025. 255 funds tracked by Wall St. Rank hold IOVA as of Q2 2025.

  • Rialto Wealth Management reported no remaining Iovance Biotherapeutics position as of Q2 2025 after selling out during the quarter.
  • Rialto Wealth Management sold 131 Iovance Biotherapeutics shares in Q2 2025, an estimated $437.
  • Rialto Wealth Management first reported a position in Iovance Biotherapeutics in Q1 2025 and held it in 1 quarter.
  • Rialto Wealth Management's Iovance Biotherapeutics position peaked at $437 in Q1 2025.
  • 255 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2025.

Based on Rialto Wealth Management's 13F filing for Q2 2025, filed 6 Aug 2025.